SWAMPSCOTT, Mass., May 10, 2011 (GLOBE NEWSWIRE) -- Patrick S. Smith, President and Chief Executive Officer of Curaxis Pharmaceutical Corporation (OTCBB:CURX) ("Curaxis" or the "Company"), commented today on a paper recently published by the National Institute of Health (NIH) entitled "Gonadotropin-releasing hormone receptor system: modulatory role in aging and neurodegeneration."
Mr. Smith noted, "The NIH's paper provides important new validation for Curaxis' science, which is based on lowering levels of luteinizing hormone (LH) to treat Alzheimer's disease. The NIH's paper concludes that increases in LH levels as we age '…promotes biochemical and cellular changes consistent with the neurodegenerative changes observed in the AD brain.' Memryte, which is our novel candidate to treat Alzheimer's and which lowers elevated levels of LH, has demonstrated great promise in treating Alzheimer's in both animal testing and in human clinical trials. Our research indicates that our approach works to stabilize cognition and reduce inflammation, beta amyloid accumulation, tau phosphorylation and oxidative stress, all of which we believe are downstream events for which elevated LH levels serve as the catalyst. We look forward to further demonstrating the potential of Memryte as we anticipate moving into advanced clinical trials later this year," Mr. Smith concluded.
Curaxis is an emerging specialty pharmaceutical company with a hormone drug product candidate for the treatment of Alzheimer's disease and multiple cancers. Curaxis' therapeutic platform is based on the hypothesis that many diseases of aging may be caused by age-related changes in the function of the hypothalamic-pituitary-gonadal (HPG) axis. The HPG axis is a hormonal endocrine feedback loop that controls development, reproduction and aging in animals. This drug development platform is built on the premise that hormones associated with this feedback loop are beneficial early in life, when they promote growth and development, but are harmful later in life when the mechanism for feedback is compromised, thereby leading to disease processes, including pathologies associated with Alzheimer's disease and various cancers. We believe our discovery of similar hormonal signaling mechanisms at the cellular level in brain tissue from Alzheimer's patients and in multiple tumors will enable us to develop significant new treatments for Alzheimer's disease as well as many cancers.
Notice Regarding Forward Looking Statements
This press release includes certain "Forward-Looking Statements" within the meaning of section 21E of the Securities Exchange Act of 1934, as amended. All statements regarding potential results and future plans and objectives of Curaxis Pharmaceutical Corporation are forward-looking statements that involve various risks and uncertainties. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. Important factors that could cause actual results to differ materially from our expectations include, but are not limited to, those factors that are disclosed under the heading "Risk Factors" and elsewhere in our documents filed from time to time with the U.S. Securities and Exchange Commission. Other risk factors may include, but are not limited to, fluctuation in quarterly results, and increased competition in our operations, our ability to continue operations as scheduled, and our ability to protect the proprietary technology we use. Further, the Company operates in an industry sector where securities values are highly volatile and may be influenced by economic and other factors beyond the Company's control, such as announcements by competitors and service providers.
The contents of this press release are presented as a general overview of the Company. It is intended only to contain general information regarding the Company and its business and does not purport to provide complete disclosure or analysis of all matters, which may be relevant to a decision to make an investment, including all risk factors or similar considerations. Although the information is believed current as of the date herein, the information may be subject to change, amendment or supplementation, and the Company does not expect, and assumes no obligation, to update or otherwise revise the information herein.
CONTACT: Curaxis Pharmaceutical Corporation Company Contact: David Corcoran Email: firstname.lastname@example.org European Advisor: Andreea Porcelli Phone: 0035-2-2088-0289 Email: email@example.com